Table 1 Patient characteristics (n = 439)
BCR(+) | n = 34 | BCR(−) | n = 405 | ||||
|---|---|---|---|---|---|---|---|
Median | IQR | Median | IQR | Median | IQR | ||
Age | (years) | 59 | 55-65 | 62 | 56-66 | 59 | 55-64 |
BMI | (kg/m2) | 28.1 | 25.6-31.2 | 29.3 | 25.5-33.2 | 28 | 25.7-31.1 |
Preoperative PSA (ng/ml) | 4.9 | 3.9-6.3 | 6.7 | 4.5-13.2 | 4.9 | 3.9-6.0 | |
Follow up time (months) | 16 | 6-34 | 33 | 3-49 | 15 | 6-33 | |
n | % | BCR(+) | n = 34 | BCR(−) | n = 405 | ||
Clinical Stage | |||||||
T1c | 342 | 77.9% | 22 | 64.7% | 320 | 79.0% | |
T2a | 65 | 14.8% | 5 | 14.7% | 60 | 14.8% | |
T2b | 24 | 5.5% | 5 | 14.7% | 19 | 4.7% | |
T2c | 7 | 1.6% | 2 | 5.9% | 5 | 1.2% | |
T3a | 1 | 0.2% | 0 | 0.0% | 1 | 0.2% | |
Clinical Gleason | |||||||
≤6 | 216 | 49.2% | 8 | 23.5% | 208 | 51.4% | |
7 | 202 | 46.0% | 21 | 61.8% | 281 | 69.4% | |
≥8 | 21 | 4.8% | 5 | 14.7% | 16 | 4.0% | |
Pathological Stage | |||||||
T2a | 50 | 11.4% | 0 | 0.0% | 50 | 12.3% | |
T2b | 7 | 1.6% | 0 | 0.0% | 7 | 1.7% | |
T2c | 280 | 63.8% | 10 | 29.4% | 270 | 66.7% | |
T3a | 75 | 17.1% | 12 | 35.3% | 63 | 15.6% | |
T3b | 24 | 5.5% | 9 | 26.5% | 15 | 3.7% | |
T4 | 3 | 0.7% | 3 | 8.8% | 0 | 0.0% | |
Pathological Gleason | |||||||
≤6 | 157 | 35.8% | 0 | 0.0% | 157 | 38.8% | |
7 | 241 | 54.9% | 6 | 17.6% | 235 | 58.0% | |
≥8 | 41 | 9.3% | 28 | 82.4% | 13 | 3.2% | |
Operative period | |||||||
2005-2007 | 102 | 23.2% | 14 | 41.2% | 88 | 21.7% | |
2008-2010 | 203 | 46.2% | 13 | 38.2% | 190 | 46.9% | |
2011-2013 | 134 | 30.5% | 4 | 11.8% | 130 | 32.1% | |
Positive Surgical Margin | 119 | 27.1% | 20 | 58.8% | |||
BCR | 34 | 7.7% | 34 | 100.0% | |||
PSA > 0.2 | 31 | 7.1% | 31 | 91.2% | |||
SalvageXRT | 20 | 4.6% | 20 | 58.8% | |||